Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
ASCO 2016: Advances in Prostate Cancer

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.16
Views: 3979

Prof Karim Fizazi, Prof Maria De Santis, Prof Bertrand Tombal and Dr Mark Beresford

Prof Karim Fizazi (Cancer Medicine at the Institut Gustave Roussy, Villejuif, France) chairs a discussion with Prof Maria De Santis (Warwick Medical School Cancer Research, University of Warwick, UK), Prof Bertrand Tombal (Saint-Luc Hospital, Brussels, Belgium) and Dr Mark Beresford (Royal United Hospitals Bath, Bath, UK).

The first study looked at the expanded analysis of the Johns Hopkins cohort and whether we can predict response to treatment with abiraterone acetate (AA) and enzalutamide (ENZA) in castration-resistant prostate cancer (CRPC) depending on AR-V7 and levels of circulating tumour cells.

The results led the panel to suggest that we may now have a biomarker that can help guide treatment decisions.

The panel then discussed whether clinical manipulation of AA metabolites might be an approach to optimising anti-androgen therapy.

The study presented on Day 2 led the panel to suggest that while clinically fine tuning AA metabolism is an intriguing area, combination therapies with AA should likely be the focus for the future.

This sentiment led the panel on to the next study demonstrating that AA in combination with ipatasertib improves both radiographic progression free survival (rPFS) and overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC), compared to AA alone.

The safety profile of maintaining AA along with docetaxel in asymptomatic/minimally symptomatic mCRPC patients was then evaluated in the ABIDO-SOGUG trial.

Here, the panel noted how when combined with chemotherapy in this setting, more frequent toxicities may be seen.

The effects of the combination of AA and ENZU were looked at again, this time on cognitive impairment and depressive symptoms in patients with mCRPC and the considerations of treatment for patients now and in the future when we move to adjuvant therapy.

Finally, the panel discussed the results from the AFFIRM study and the relationship with quality of life with the use of docetaxel.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation